Partner Content Partner Content SMi’ 10th Annual Social Media in Pharma – Pfizer Exclusive S... Social Media in Pharma
Partner Content Partner Content How Doctors’ Conversations Differ From Private to Public Soc... ocial Media in Pharma
Partner Content Partner Content Driving Patient Engagement Through Powerful Social Strategie... SMi’s Social Media in Pharma
Partner Content Partner Content 7 Key Reasons to Attend Social Media in the Pharmaceutical I... SMi's 10th Annual Conference
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.